Stay updated on Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.

Latest updates to the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page
- Check4 days agoChange DetectedAdded a new publication citation to the Publications section (Dermatol Ther, 2026 Mar 16) and updated the page revision to v3.5.0 (from v3.4.3).SummaryDifference0.1%

- Check11 days agoChange DetectedRevision: v3.4.3 implemented, replacing v3.4.2.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page layout and sections appear reorganized in the new screenshot. No core study details, eligibility criteria, outcomes, or results have been added or removed.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page shows a site revision indicator (Revision: v3.4.2) and removal of prior notices about funding and operating status, with no change to the study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check47 days agoChange DetectedAdded a site-wide notice about government funding and the NIH Clinical Center's status. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check54 days agoChange DetectedAdded a glossary toggle and new metadata lines: Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed the previous lines: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.